Publications

BibTex format

@article{Finch:2022:10.1371/journal.pbio.3001531,
author = {Finch, E and Lowe, R and Fischinger, S and de, St Aubin M and Siddiqui, SM and Dayal, D and Loesche, MA and Rhee, J and Beger, S and Hu, Y and Gluck, MJ and Mormann, B and Hasdianda, MA and Musk, ER and Alter, G and Menon, AS and Nilles, EJ and Kucharski, AJ and CMMID, COVID-19 working group and the SpaceX COVID-19 Cohort Collaborative},
doi = {10.1371/journal.pbio.3001531},
journal = {PLoS Biol},
title = {SARS-CoV-2 antibodies protect against reinfection for at least 6 months in a multicentre seroepidemiological workplace cohort.},
url = {http://dx.doi.org/10.1371/journal.pbio.3001531},
volume = {20},
year = {2022}
}

Download

RIS format (EndNote, RefMan)

TY  - JOUR
AB  - Identifying the potential for SARS-CoV-2 reinfection is crucial for understanding possible long-term epidemic dynamics. We analysed longitudinal PCR and serological testing data from a prospective cohort of 4,411 United States employees in 4 states between April 2020 and February 2021. We conducted a multivariable logistic regression investigating the association between baseline serological status and subsequent PCR test result in order to calculate an odds ratio for reinfection. We estimated an odds ratio for reinfection ranging from 0.14 (95% CI: 0.019 to 0.63) to 0.28 (95% CI: 0.05 to 1.1), implying that the presence of SARS-CoV-2 antibodies at baseline is associated with around 72% to 86% reduced odds of a subsequent PCR positive test based on our point estimates. This suggests that primary infection with SARS-CoV-2 provides protection against reinfection in the majority of individuals, at least over a 6-month time period. We also highlight 2 major sources of bias and uncertainty to be considered when estimating the relative risk of reinfection, confounders and the choice of baseline time point, and show how to account for both in reinfection analysis.
AU  - Finch,E
AU  - Lowe,R
AU  - Fischinger,S
AU  - de,St Aubin M
AU  - Siddiqui,SM
AU  - Dayal,D
AU  - Loesche,MA
AU  - Rhee,J
AU  - Beger,S
AU  - Hu,Y
AU  - Gluck,MJ
AU  - Mormann,B
AU  - Hasdianda,MA
AU  - Musk,ER
AU  - Alter,G
AU  - Menon,AS
AU  - Nilles,EJ
AU  - Kucharski,AJ
AU  - CMMID,COVID-19 working group and the SpaceX COVID-19 Cohort Collaborative
DO  - 10.1371/journal.pbio.3001531
PY  - 2022///
TI  - SARS-CoV-2 antibodies protect against reinfection for at least 6 months in a multicentre seroepidemiological workplace cohort.
T2  - PLoS Biol
UR  - http://dx.doi.org/10.1371/journal.pbio.3001531
UR  - https://www.ncbi.nlm.nih.gov/pubmed/35143473
VL  - 20
ER  -

Download

DrThibautJombart

Contact

Location

Summary

Citation

BibTex format

RIS format (EndNote, RefMan)